Experimental HCV Drugs
Experimental HCV Drugs
Samatasvir + Simeprevir for Hepatitis C Shows High Early Cure Rate
- Details
- Category: Experimental HCV Drugs
- Published on Thursday, 23 January 2014 00:00
- Written by Idenix
An interferon-free regimen containing Idenix Pharmaceuticals' hepatitis C virus NS5A inhibitor samatasvir (formerly IDX719) plus the recently approved HCV protease inhibitor simeprevir (Olysio) and ribavirin demonstrated an 85% sustained response rate at 4 weeks post-treatment in the Phase 2 HELIX-1 trial, according to a company announcement.
AbbVie All-oral Combination Cures Most Hepatitis C Patients in Phase 2 Study
- Details
- Category: Experimental HCV Drugs
- Published on Thursday, 16 January 2014 00:00
- Written by Liz Highleyman
An all-oral regimen of AbbVie's experimental HCV drugs ABT-450, ABT-333, and ABT-367 plus ribavirin was well-tolerated and cured 88% of genotype 1 hepatitis C patients with only 8 weeks of therapy, rising to 95% with 12 weeks, according to a report in the January 16, 2014, New England Journal of Medicine.
Daclatasvir + VX-135 May Cure 80% of Genotype 1 Hepatitis C Patients
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 10 January 2014 00:00
- Written by Vertex & BMS
An all-oral regimen of Bristol-Myers Squibb's hepatitis C virus (HCV) NS4A inhibitor daclatasvir plus Vertex's experimental nucleotide polymerase inhibitor VX-135 -- without interferon or ribavirin -- produced early sustained virological response at 4 weeks post-treatment in 83% of previously untreated genotype 1 patients in a small study, Vertex announced this week.
Daclatasvir + Sofosbuvir Shows High Hep C Cure Rate, New Studies Underway
- Details
- Category: Experimental HCV Drugs
- Published on Thursday, 16 January 2014 00:00
- Written by Liz Highleyman
A dual oral regimen of daclatasvir plus sofosbuvir cured more than 90% of chronic hepatitis C patients without interferon or ribavirin, according to a report in the January 16, 2014, New England Journal of Medicine. A series of new studies of this combination in difficult-to-treat groups including HIV/HCV coinfected people and liver transplant recipients are underway.
HIVandHepatitis.com Complete 2013 Conference Coverage
- Details
- Category: HIV Treatment
- Published on Monday, 30 December 2013 00:00
- Written by Liz Highleyman
HIVandHepatitis.com 2013 conference and meeting coverage.
12/30/13
Web Design and Development by